Disease Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Therapy Indication/Tumor Type Response Type Profile Response Detail
KDR R1032Q Pazopanib basal cell carcinoma predicted - sensitive detail...
BRAF V600E Dabrafenib + Trametinib basal cell carcinoma predicted - sensitive detail...
Clinical Trial Phase Therapies Title Recruitment Status Covered Countries Other Countries
NCT01367665 Phase II Vismodegib STEVIE: A Study of Vismodegib in Patients With Locally Advanced or Metastatic Basal Cell Carcinoma Completed ITA | FRA | ESP | DEU | CAN | BEL | AUT 30
NCT01543581 Phase II Vismodegib Vismodegib for Treatment of Basal Cell Carcinoma (Erivedge) Completed 0
NCT01700049 Phase II Vismodegib Study Evaluating the Efficacy of Oral Vismodegib in Various Histologic Subtypes Completed USA 0
NCT01815840 Phase II Vismodegib A Study of Two Vismodegib Regimens in Patients With Multiple Basal Cell Carcinomas Completed USA | ITA | FRA | ESP | DEU | CAN | AUT 3
NCT01898598 Phase II Vismodegib A Study of Vismodegib With Surgery in Patients With Previously Untreated Basal Cell Carcinoma Terminated USA 0
NCT02067104 Phase II Vismodegib Vismodegib in Basal Cell Carcinomas (BCC) Chemoprevention Terminated USA 0
NCT02120677 Phase I Itraconazole Topical Itraconazole in the Treatment of Basal Cell Carcinoma Completed USA 0
NCT02303041 Phase I Buparlisib + Sonidegib Erismodegib and Buparlisib in Treating Patients With Advanced or Metastatic Basal Cell Carcinoma Terminated USA 0
NCT02436408 FDA approved Vismodegib VISmodegib for ORbital and Periocular Basal Cell Carcinoma Completed USA 0
NCT02639117 Phase I Vismodegib Photodynamic Therapy and Vismodegib for Multiple Basal Cell Carcinomas Completed USA 0
NCT02690948 Phase II Pembrolizumab + Vismodegib Pembrolizumab Pembrolizumab With or Without Vismodegib in Treating Metastatic or Unresectable Basal Cell Skin Cancer Completed USA 0
NCT02699723 Phase I Arsenic trioxide + Itraconazole Arsenic Trioxide and Itraconazole in Treating Patients With Advanced Basal Cell Cancer Withdrawn 0
NCT02735356 Phase I Itraconazole Topical Itraconazole in Treating Patients With Basal Cell Cancer Completed USA 0
NCT02978625 Phase II Nivolumab + Talimogene laherparepvec Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers Recruiting USA 0
NCT03132636 Phase II Cemiplimab PD-1 in Patients With Advanced Basal Cell Carcinoma Who Experienced Progression of Disease on Hedgehog Pathway Inhibitor Therapy, or Were Intolerant of Prior Hedgehog Pathway Inhibitor Therapy Active, not recruiting USA | ITA | FRA | ESP | DEU | CAN | BEL | AUT 2
NCT03220347 Phase I CC-90010 A Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of CC-90010 in Subjects With Advanced Solid Tumors and Relapsed/Refractory Non-Hodgkin's Lymphomas Active, not recruiting ITA | FRA | ESP 1
NCT03517488 Phase I XmAb20717 A Study of XmAb20717 in Subjects With Selected Advanced Solid Tumors (DUET-2) Active, not recruiting USA 0
NCT03521830 Phase II Nivolumab Ipilimumab + Nivolumab Nivolumab Alone or Plus Ipilimumab for Patients With Locally-Advanced Unresectable or Metastatic Basal Cell Carcinoma Recruiting USA 0
NCT03534947 Phase II Imiquimod + Sonidegib Sonidegib A Study to Evaluate Neoadjuvant Sonidegib Followed by Surgery or Imiquimod in the Management of Basal Cell Carcinoma (SONIB) Recruiting 1
NCT03610022 FDA approved Vismodegib Relationship Between Pharmacokinetics and Safety of Vismodegib - OPTIVISMO-1 (OPTIVISMO-1) Recruiting FRA 0
NCT03767348 Phase Ib/II Nivolumab + RP1 RP1 Study of RP1 Monotherapy and RP1 in Combination With Nivolumab Recruiting USA | FRA | ESP | DEU 1
NCT03816332 Phase I Ipilimumab + Nivolumab + Prednisone + Tacrolimus Tacrolimus, Nivolumab, and Ipilimumab in Treating Kidney Transplant Recipients With Selected Unresectable or Metastatic Cancers Suspended USA 0
NCT03897036 Phase I Silmitasertib Treatment Duration Increment and Pharmacodynamic Study of CX-4945 in Patients With Basal Cell Carcinoma (BCC) Recruiting USA 0
NCT04089527 Phase I FT-1101 Study to Evaluate the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic of CC-95775 in Subjects With Advanced Solid Tumors and Relapsed/Refractory Non-Hodgkin Lymphoma Completed FRA | ESP 0
NCT04155190 Phase II Patidegib topical gel An Study of Patidegib Topical Gel, 2%, for the Reduction of Disease Burden of Persistently Developing Basal Cell Carcinomas in Patients With Non-Gorlin High Frequency BCC Terminated USA 0
NCT04323202 Phase I Pembrolizumab Neoadjuvant-Adjuvant Pembrolizumab in Resectable Advanced Basal Cell Carcinoma of H&N Recruiting USA 0
NCT04416516 Phase II ASN002 Safety and Efficacy of ASN-002 Combined With a Hedgehog Pathway Inhibitor Recruiting 1
NCT04669808 Phase II Cotsiranib Open Label, Dose Escalation Study for the Safety and Efficacy of STP705 in Adult Patients With Basal Cell Carcinoma Recruiting USA 0
NCT04806646 Phase II Sonidegib Tailored Sonidegib Schedule After Complete Response in BCC (SONIBEC) Recruiting ITA 0
NCT04925713 Phase I IFx-Hu2.0 IFx-Hu2.0 for the Treatment of Patients With Skin Cancer Completed USA 0
NCT05188729 Phase II LTX-315 Open-Label Proof of Concept Study of LTX-315 in Basal Cell Carcinoma Recruiting USA 0
NCT05329792 Phase II Daromun L19IL2/L19TNF in Skin Cancer Patients Not yet recruiting FRA 0